NorthCrest Asset Manangement’s Cytek Biosciences CTKB Stock Holding History

NorthCrest Asset Manangement’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.9K	Sell	13,923 -1,293	-8%	-$5.52K	﹤0.01%	903
2026 Q1	$68.9K	Buy	15,216 +927	+6%	+$4.38K	﹤0.01%	754
2025 Q4	$74.4K	Buy	14,289 +7	+0%	+$33	﹤0.01%	809
2025 Q3	$54.1K	Sell	14,282 -976	-6%	-$3.66K	﹤0.01%	739
2025 Q2	$57.4K	Sell	15,258 -15,519	-50%	-$51.7K	﹤0.01%	622
2025 Q1	$123K	Sell	30,777 -1,407	-4%	-$7.29K	﹤0.01%	581
2024 Q4	$209K	Sell	32,184 -18,983	-37%	-$113K	0.01%	543
2024 Q3	$283K	Buy	51,167 +17	+0%	+$96	0.01%	492
2024 Q2	$285K	Hold	51,150	–	–	0.01%	461
2024 Q1	$343K	Sell	51,150 -900	-2%	-$7.12K	0.01%	430
2023 Q4	$475K	Hold	52,050	–	–	0.02%	388
2023 Q3	$287K	Sell	52,050 -1,000	-2%	-$8.02K	0.01%	445
2023 Q2	$453K	Hold	53,050	–	–	0.02%	377
2023 Q1	$488K	Buy	53,050 +1,000	+2%	+$10.8K	0.02%	363
2022 Q4	$531K	Buy	+52,050	New	+$700K	0.03%	267

Other funds holding CTKB

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

NorthCrest Asset Manangement's CTKB Position: Q2 2026 in Review

NorthCrest Asset Manangement reduced its Cytek Biosciences (CTKB) stake by 8.5% in Q2 2026, selling an estimated $5.52K and leaving 13,923 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

NorthCrest Asset Manangement first reported a position in CTKB in Q4 2022 and has held it in 15 quarters since. The position peaked at $531K in Q4 2022. 14 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

NorthCrest Asset Manangement held 13,923 shares of Cytek Biosciences worth $63.9K as of Q2 2026.
NorthCrest Asset Manangement sold 1,293 Cytek Biosciences shares in Q2 2026, an estimated $5.52K.
Cytek Biosciences made up ﹤0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #903 holding.
NorthCrest Asset Manangement first reported a position in Cytek Biosciences in Q4 2022 and has held it in 15 quarters since.
NorthCrest Asset Manangement's Cytek Biosciences position peaked at $531K in Q4 2022.
14 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.